washlander
- 27 Sep 2003 08:38
Any thoughts on this company. Seemes to have good phase11 trail results in both their anti obesity drug and Irratable bowel syndrome drugs.
Much appreciated
Makes a change for a bio tech com to do well.
Thanks in advance
piniky0190
- 12 Nov 2003 10:25
- 80 of 109
Rise on bid rumours (see Guardian, Indie etc) - supposedly at 2.20 but denied by the company! 2.20 is way too cheap so dont expect much to come out of this - but a bid war would be fun (and quite bloody!!)
ckmtang
- 12 Nov 2003 12:34
- 81 of 109
stiil looking good. touching 2 pound soon.
ckmtang
- 17 Nov 2003 10:50
- 82 of 109
What's wrong today???
washlander
- 17 Nov 2003 11:48
- 83 of 109
Just the market in general doing bad. However biotecs seem to be getting the worst of it.
ckmtang
- 17 Nov 2003 11:50
- 84 of 109
do anyone know when will AZm have news next time, beucase it seemed dind`t hear anything for long
washlander
- 17 Nov 2003 12:23
- 85 of 109
Other then progress reports, phase 111 results will not be available until middle of next year. However several pharma's will be keeping an eye on them with a view to sealing contracts before then if the trials are going in the right direction. Their irritable bowl syndrom drug will give good leverage in future contracts for their anti obesity drug.
ckmtang
- 19 Nov 2003 13:29
- 86 of 109
drop a bit today
ckmtang
- 01 Dec 2003 09:56
- 87 of 109
Do anyone know what;s wrong today?
rayrac
- 01 Dec 2003 12:56
- 88 of 109
ckmtang, you from China? Becorse eye does no not what is up/down with AZM. Does no panick, it is get beter soun!
OK
boroboys
- 01 Dec 2003 19:37
- 89 of 109
cpeck12
- 16 Jan 2004 12:43
- 90 of 109
Bargain hunters out there what do you think of this one as of NOW?
cpeck12
- 16 Jan 2004 13:42
- 91 of 109
Spotted the increase in intuitional interest?
13 Jan
1,715,900 Fidelity Management & Research Company HSBC
1,783,289 Fidelity Investment Services Ltd. Chase Manhattan Bank
London
4,915,096 Fidelity International Limited HSBC Client Holdings
Nominee (UK) Limited
260,800 Fidelity International Limited Chase Manhattan Bank
London
45,119 Fidelity International Limited State Street Bank & Trust
24 Dec
1,715,900 Fidelity Management & Research Company HSBC
1,783,289 Fidelity Investment Services Ltd. Chase Manhattan Bank London
3,702,062 Fidelity International Limited HSBC Client Holdings Nominee (UK) Ltd
162,400 Fidelity International Limited Chase Manhattan Bank London
cpeck12
- 30 Jan 2004 12:31
- 92 of 109
Not bad for 6.7% rise today. More than 10% since 16 Jan
cpeck12
- 30 Jan 2004 12:32
- 93 of 109
260 for the next level.
boroboys
- 30 Jan 2004 12:35
- 94 of 109
I agree, 260 and 300p will be their
boro
rayrac
- 31 Jan 2004 11:36
- 95 of 109
Bit of nonsense from the Times, they haven't a clue! There's even more rubbish from Tempus. But it is more heartening news from the FT and Daily Express!
January 31, 2004
Fat cheque from Japan for UK biotech's obesity pill
By Ingrid Mansell
ALIZYME, one of the UKs biggest biotech hopes, said Japans top pharmaceutical company was preparing to develop the companys fledgeling anti-obesity drug under a $42 million (23 million) deal.
The news sent Alizyme shares surging 13.5p to 213.5p yesterday, a level not seen since the biotech bubble burst in 2000. The stock has risen eightfold in the past nine months.
Alizyme said Takeda Chemical Industries had handed over $3 million to exercise an option to develop and market ATL-962 in Japan, following positive European trials for the anti-obesity drug.
The payment comes on top of $2 million paid by Takeda to Alizyme last August, when the licensing agreement between the two companies was struck. A further $37 million is payable on future milestones, and the UK firm has also secured double-digit royalties on sales of the drug in Japan. Takeda will also have to foot the bill for all the drugs development costs in Japan.
ATL-962 works like its main rival Xenical, developed by Switzerlands Roche, by blocking fat being absorbed into the blood. But Alizyme claims that clinical trials showed ATL-962 is as effective as Xenical but with a far lower incidence of adverse side-effects.
Tim McCarthy, finance director, said Takedas decision to take the licensing deal to the next level augured well for the drugs licensing prospects worldwide.
Alizyme is in talks with several top drugmakers about a worldwide licensing deal but Mr McCarthy declined to say when an agreement might be reached. He said, though, that the company hoped to launch the drug in 2007.
Analysts estimated peak annual sales for ATL-962 at more than $1 billion.
cpeck12
- 01 Feb 2004 16:22
- 96 of 109
FT and IC are the two to look out for IMHO. And that does not mean that the rest can be ignored!!!
drum
- 02 Feb 2004 10:01
- 97 of 109
drum
does anyone know what's caused the price drop today? 11p down so far.
cpeck12
- 02 Feb 2004 10:14
- 98 of 109
I believe its nothing major. Some profit taking going on.
cpeck12
- 02 Feb 2004 10:47
- 99 of 109
Time to alert bargin hunters!!! 196.50